Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AstraZeneca is a global biopharma company with a longstanding strategic research partnership with the University of Oxford. Together we are tackling a broad range of biomedical questions through collaborative research projects with the goal of accelerating drug discovery programmes.

About the Oxford-AstraZeneca Alliance

AstraZeneca (AZ) and Oxford have a long history of collaboration through involvement in studentship programmes, access to research tools/molecules, sponsored research projects, research consortia and clinical trials. The company also support our innovation ecosystem and provide steer to our biomedical translational research portfolio as active members of our industry Experts in Residence programme.

Together we have joined forces to bring the COVID-19 vaccine Vaxzervria to the market with a focus on the provision of vaccines to LMIC countries and AZ are partners of the new University Pandemic Sciences Institute.

The Business Partnerships Office work closely with the alliance management and business development teams at AstraZeneca to establish new connections for the company within Oxford, to promote funding and molecule sharing opportunities and to oversee governance of existing programmes.